Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.

Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.

Abstract: Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and/or compounds of formula I or II Screening assays to identify compounds that may be useful for inhibiting and/or eliminating AML initiating cells using AhR modulators and/or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.

Abstract: A magnetic drape comprises a drape body made of a flexible material. The drape body has a panel portion having an undersurface adapted to be laid on an uneven body and a top surface, and a given thickness between the undersurface and the top surface. A plurality of magnet units are within the flexible material of the drape body, with each said magnet unit comprising a shielding material in the shape of a cup oriented to have a bottom wall facing toward the undersurface of the drape body, and a magnet received at least partially in the cup. The magnet comprises two or more sections arranged to expose opposite polarity on a top surface of the magnetic drape, with each said section having opposite polarities oriented vertically.

Abstract: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.

Abstract: Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described.

Abstract: A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the polypeptide to ubiquitin-proteasome degradation.

Abstract: The present invention relates to an apparatus and a method for measuring a displacement in vivo in situ of an eye, along with a method of assessing of an eye condition. More particularly, the apparatus and method of the present invention permits measurements of a displacement of at least two points in proximity of an optic disc, in the eye of a patient. For doing so, the apparatus uses a probing unit, an analog/digital converter and an analyzer. The displacement measured may include a pulsatile displacement of the lamina cribrosa, so as to perform early assessment of an eye condition.

Abstract: The present invention relates to an apparatus and a method for measuring a displacement in vivo in situ of an eye, along with a method of assessing of an eye condition. More particularly, the apparatus and method of the present invention permits measurements of a displacement of at least two points in proximity of an optic disc, in the eye of a patient. For doing so, the apparatus uses a probing unit, an analog/digital converter and an analyzer. The displacement measured may include a pulsatile displacement of the lamina cribrosa, so as to perform early assessment of an eye condition.